12:00 AM
Mar 22, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Status

MG98: Began Phase I study

MethylGene Inc., Montreal, Quebec
Product: MG98
Business: Cancer
Therapeutic category: Antisense
Target: DNA methyltransferase...

Read the full 58 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >